BIOPHTA

BIOPHTA is an early-stage, private biotech company targeting the $50B+ global ophthalmic market with a disruptive drug delivery platform. The company's core innovation is a first-of-its-kind, 7-day sustained-release ocular insert designed to replace inefficient daily eye drops and painful intraocular injections, thereby solving the critical problem of patient non-adherence. Founded by seasoned executives with deep ophthalmic industry experience, BIOPHTA is positioned to create a new standard of care for both front-of-the-eye (e.g., glaucoma) and back-of-the-eye (e.g., AMD, DME) diseases. Its platform technology has the potential to improve drug efficacy, enhance patient quality of life, and reduce the overall burden on healthcare systems.

A self-administered, dry mini-tablet ocular insert that instantly forms a gel upon contact with the eye. It adheres to the ocular surface and provides continuous, controlled microdosing of medication for up to 7 days.

Competition includes other companies developing sustained-release ophthalmic technologies, such as punctal plugs (e.g., Ocular Therapeutix's Dextenza), injectable long-acting depots, and contact lens-based delivery systems. BIOPHTA differentiates with its proposed 7-day, self-administered, gel-forming insert designed for both anterior and posterior segment delivery.